DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruitingOBSERVATIONAL
Enrollment

85

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pulmonary Disease
Interventions
OTHER

Institutional standard of care

Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)

OTHER

Biosamples of airway and blood

Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.

Trial Locations (19)

15232

University of Pittsburgh Medical Center, Pittsburgh

19103

American College of Radiology [Administrative Site], Philadelphia

19104

University of Pennsylvania School of Medicine, Philadelphia

19140

Temple University, Philadelphia

20889

Walter Reed Army Medical Center, Bethesda

23708

Naval Medical Center Portsmouth, Portsmouth

26505

West Virginia University, Morgantown

35233

University of Alabama, Birmingham, Birmingham

37232

VA Tennessee Valley Healthcare System, Nashville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

52242

University of Iowa, Iowa City

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center [Administrative Site], Houston

90095

University of California Los Angeles, Los Angeles

VA Greater LA Healthcare System, Los Angeles

92134

Naval Medical Center San Diego, San Diego

02110

VA Boston Healthcare System, Boston

02912

Brown University [Administrative Site], Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Johnson & Johnson

INDUSTRY

collaborator

American College of Radiology Imaging Network

NETWORK

lead

Boston University

OTHER